Scientists hunt for clues to breast cancer treatment resistance
NCT ID NCT06518382
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examines tumor samples from 10 people with HER2-positive breast cancer who still had cancer after standard chemotherapy and trastuzumab. Researchers compare tissue taken before and after treatment to identify markers of resistance. No new treatments are given; the goal is to better understand why some cancers don't respond.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
IRCCS San Raffaele Hospital
RECRUITINGMilan, Lombardy, 20132, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer
- Can a new drug outsmart resistant breast cancer?
- Can a new targeted drug outperform the current standard for HER2-Positive breast cancer?